$DVA
DAVITA INC. Stock $dva

$dva Overview Financials Valuation SEC Filings Company Website

2017 Q4 Form 10-Q Financial Statement

#000092706617000088 Filed on November 07, 2017

Income Statement

Concept	2017 Q4	2017 Q3	2016 Q4
Revenue	$2.781B	$2.765B	$2.699B
YoY Change	3.02%	1.46%	-23.61%
Cost Of Revenue	$1.942B	$1.952B	-$519.4M
YoY Change	-473.84%	-27.65%	-120.65%
Gross Profit	$839.2M	$813.5M	$197.5M
YoY Change	324.91%	-21.24%	-80.61%
Gross Profit Margin	30.18%	29.42%	7.32%
Selling, General & Admin	$259.8M	$270.2M	-$105.6M
YoY Change	-346.02%	-34.21%	-125.91%
% of Gross Profit	30.96%	33.21%	-53.47%
Research & Development
YoY Change
% of Gross Profit
Depreciation & Amortization	$184.0M	$203.3M	$188.8M
YoY Change	-2.54%	11.83%	15.62%
% of Gross Profit	21.93%	24.99%	95.59%
Operating Expenses	$404.1M	$412.9M	-$127.5M
YoY Change	-416.94%	-30.3%	-122.33%
Operating Profit	$150.3M	$395.3M	$363.4M
YoY Change	-58.64%	-51.38%	48.38%
Interest Expense	-$112.2M	-$114.6M	-$92.00M
YoY Change	21.96%	14.14%	-3.87%
% of Operating Profit	-74.63%	-28.99%	-25.31%
Other Income/Expense, Net	$5.500M	$3.396M	-$600.0K
YoY Change	-1016.67%	81.02%	-113.04%
Pretax Income	$46.83M	$289.4M	$259.7M
YoY Change	-81.97%	-59.26%	77.48%
Income Tax	$101.7M	$90.55M	$65.80M
% Of Pretax Income	217.19%	31.29%	25.34%
Net Earnings	$303.4M	-$214.5M	$157.7M
YoY Change	92.36%	-137.54%	-2728.77%
Net Earnings / Revenue	10.91%	-7.76%	5.84%
Basic Earnings Per Share	$1.66	-$1.14	$0.81
Diluted Earnings Per Share	$1.64	-$1.12	$0.80
COMMON SHARES
Basic Shares Outstanding	183.3M shares	188.9M shares	197.4M
Diluted Shares Outstanding		191.4M shares

Balance Sheet

Concept	2017 Q4	2017 Q3	2016 Q4
SHORT-TERM ASSETS
Cash & Short-Term Investments	$578.8M	$1.104B	$1.012B
YoY Change	-42.8%	-31.65%	-41.92%
Cash & Equivalents	$508.2M	$846.1M	$674.8M
Short-Term Investments	$70.53M	$257.5M	$337.0M
Other Short-Term Assets	$112.1M	$205.2M	$99.51M
YoY Change	12.61%	15.94%	-47.71%
Inventory	$181.8M	$154.4M	$160.4M
Prepaid Expenses	$104.7M		$96.82M
Receivables	$1.715B	$2.091B	$1.504B
Other Receivables	$399.3M	$599.4M	$288.2M
Total Short-Term Assets	$8.771B	$4.034B	$3.995B
YoY Change	119.56%	-5.35%	-11.29%
LONG-TERM ASSETS
Property, Plant & Equipment	$3.149B	$3.386B	$2.864B
YoY Change	9.95%	11.2%	2.7%
Goodwill	$6.610B	$9.416B	$6.015B
YoY Change	9.89%	0.35%	2.02%
Intangibles	$113.8M	$1.451B	$73.50M
YoY Change	54.86%	-7.94%	-95.64%
Long-Term Investments	$0.00	$0.00	$0.00
YoY Change		-100.0%	-100.0%
Other Assets	$47.29M	$61.64M	$33.86M
YoY Change	39.67%	43.41%	-53.97%
Total Long-Term Assets	$10.20B	$14.98B	$14.76B
YoY Change	-30.87%	2.15%	5.35%
TOTAL ASSETS
Total Short-Term Assets	$8.771B	$4.034B	$3.995B
Total Long-Term Assets	$10.20B	$14.98B	$14.76B
Total Assets	$18.97B	$19.01B	$18.76B
YoY Change	1.17%	0.46%	1.3%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$509.1M	$566.9M	$456.6M
YoY Change	11.5%	13.74%	-11.15%
Accrued Expenses	$616.0M	$775.0M	$977.0M
YoY Change	-36.95%	-8.39%	9.16%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due	$178.0M	$190.0M	$160.0M
YoY Change	11.25%	24.18%	24.03%
Total Short-Term Liabilities	$3.068B	$2.875B	$2.711B
YoY Change	13.15%	8.92%	13.0%
LONG-TERM LIABILITIES
Long-Term Debt	$9.158B	$8.909B	$8.945B
YoY Change	2.38%	-0.7%	-0.62%
Other Long-Term Liabilities	$365.3M	$548.2M	$317.4M
YoY Change	15.11%	30.24%	-27.74%
Total Long-Term Liabilities	$365.3M	$548.2M	$317.4M
YoY Change	15.11%	30.24%	-27.74%
TOTAL LIABILITIES
Total Short-Term Liabilities	$3.068B	$2.875B	$2.711B
Total Long-Term Liabilities	$365.3M	$548.2M	$317.4M
Total Liabilities	$13.08B	$13.02B	$12.93B
YoY Change	1.12%	1.42%	2.91%
SHAREHOLDERS EQUITY
Retained Earnings	$3.634B	$4.071B	$3.710B
YoY Change	-2.06%	-19.86%	-14.84%
Common Stock	$1.043B	$1.059B	$1.027B
YoY Change	1.53%	2.56%	-8.15%
Preferred Stock
YoY Change
Treasury Stock (at cost)	$0.00	$348.8M	$0.00
YoY Change		-69.62%	-100.0%
Treasury Stock Shares
Shareholders Equity	$4.690B	$4.785B	$4.648B
YoY Change
Total Liabilities & Shareholders Equity	$18.97B	$19.01B	$18.76B
YoY Change	1.17%	0.46%	1.3%

Cashflow Statement

Concept	2017 Q4	2017 Q3	2016 Q4
OPERATING ACTIVITIES
Net Income	$303.4M	-$214.5M	$157.7M
YoY Change	92.36%	-137.54%	-2728.77%
Depreciation, Depletion And Amortization	$184.0M	$203.3M	$188.8M
YoY Change	-2.54%	11.83%	15.62%
Cash From Operating Activities	$480.7M	$503.2M	$506.6M
YoY Change	-5.11%	-6.07%	16.01%
INVESTING ACTIVITIES
Capital Expenditures	-$265.5M	$240.9M	-$253.9M
YoY Change	4.57%	11.21%	3.3%
Acquisitions
YoY Change
Other Investing Activities	$6.200M	-$13.00M	$309.4M
YoY Change	-98.0%	-95.4%	-39.85%
Cash From Investing Activities	-$259.2M	-$253.9M	$55.50M
YoY Change	-567.03%	-49.12%	-79.34%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	-236.5M	-164.6M	-544.0M
YoY Change	-56.53%	-59.3%	115.1%
NET CHANGE
Cash From Operating Activities	480.7M	503.2M	506.6M
Cash From Investing Activities	-259.2M	-253.9M	55.50M
Cash From Financing Activities	-236.5M	-164.6M	-544.0M
Net Change In Cash	-15.00M	84.70M	18.10M
YoY Change	-182.87%	-123.04%	-96.0%
FREE CASH FLOW
Cash From Operating Activities	$480.7M	$503.2M	$506.6M
Capital Expenditures	-$265.5M	$240.9M	-$253.9M
Free Cash Flow	$746.2M	$262.3M	$760.5M
YoY Change	-1.88%	-17.79%	11.43%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
	dva	Adjustment Depreciation And Amortization AdjustmentDepreciationAndAmortization	531475000	USD
	dva	Adjustment Depreciation And Amortization AdjustmentDepreciationAndAmortization	593527000	USD
	dva	Adjustment Income Loss From Equity Method Investments AdjustmentIncomeLossFromEquityMethodInvestments	-16825000	USD
CY2017Q4	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	183300000	shares
	dei	Entity Filer Category EntityFilerCategory	Large Accelerated Filer
	dei	Amendment Flag AmendmentFlag	false
	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q3
	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2017
	dei	Document Period End Date DocumentPeriodEndDate	2017-09-30
	dei	Document Type DocumentType	10-Q
	dei	Entity Central Index Key EntityCentralIndexKey	0000927066
	dei	Entity Registrant Name EntityRegistrantName	DAVITA INC.
	dei	Trading Symbol TradingSymbol	DVA
	dva	Accounts Receivable Period Outstanding AccountsReceivablePeriodOutstanding	P3M
CY2016Q4	dva	Acquisition Obligations And Other Notes Payable AcquisitionObligationsAndOtherNotesPayable	117547000	USD
CY2017Q3	dva	Acquisition Obligations And Other Notes Payable AcquisitionObligationsAndOtherNotesPayable	149734000	USD
	dva	Adjustment Income Loss From Equity Method Investments AdjustmentIncomeLossFromEquityMethodInvestments	-19071000	USD
	dva	Business Combination Contingent Consideration Acquisitions BusinessCombinationContingentConsiderationAcquisitions	13524000	USD
	dva	Business Combination Contingent Consideration Acquisitions Earnouts Payments BusinessCombinationContingentConsiderationAcquisitionsEarnoutsPayments	4060000	USD
	dva	Business Combination Contingent Consideration Acquisitions Fair Value Remeasurement Gain Loss BusinessCombinationContingentConsiderationAcquisitionsFairValueRemeasurementGainLoss	1072000	USD
	dva	Debt Expense Including Debt Refinancing Charges DebtExpenseIncludingDebtRefinancingCharges	322014000	USD
CY2016Q4	dva	Discount And Deferred Finance Costs DiscountAndDeferredFinanceCosts	79861000	USD
CY2017Q3	dva	Discount And Deferred Finance Costs DiscountAndDeferredFinanceCosts	67905000	USD
	dva	Employee Service Share Based Compensation Estimated Tax Benefit From Compensation Expense EmployeeServiceShareBasedCompensationEstimatedTaxBenefitFromCompensationExpense	9769000	USD
	dva	Employee Service Share Based Compensation Estimated Tax Benefit From Compensation Expense EmployeeServiceShareBasedCompensationEstimatedTaxBenefitFromCompensationExpense	9474000	USD
CY2016Q3	dva	Equity In Earnings Loss Of Consolidated Affiliates EquityInEarningsLossOfConsolidatedAffiliates	0	USD
	dva	Equity In Earnings Loss Of Consolidated Affiliates EquityInEarningsLossOfConsolidatedAffiliates	0	USD
CY2017Q3	dva	Equity In Earnings Loss Of Consolidated Affiliates EquityInEarningsLossOfConsolidatedAffiliates	0	USD
	dva	Equity In Earnings Loss Of Consolidated Affiliates EquityInEarningsLossOfConsolidatedAffiliates	0	USD
CY2016Q3	dva	Goodwill And Other Intangible Asset Impairment Charges GoodwillAndOtherIntangibleAssetImpairmentCharges	0	USD
	dva	Goodwill And Other Intangible Asset Impairment Charges GoodwillAndOtherIntangibleAssetImpairmentCharges	253000000	USD
CY2017Q3	dva	Goodwill And Other Intangible Asset Impairment Charges GoodwillAndOtherIntangibleAssetImpairmentCharges	601040000	USD
	dva	Goodwill And Other Intangible Asset Impairment Charges GoodwillAndOtherIntangibleAssetImpairmentCharges	701523000	USD
	dva	Increase Decrease In Other Current Receivables And Other Current Assets IncreaseDecreaseInOtherCurrentReceivablesAndOtherCurrentAssets	1616000	USD
	dva	Increase Decrease In Other Current Receivables And Other Current Assets IncreaseDecreaseInOtherCurrentReceivablesAndOtherCurrentAssets	47173000	USD
CY2016Q4	dva	Investments And Other Current Assets InvestmentsAndOtherCurrentAssets	1149739000	USD
CY2017Q3	dva	Investments And Other Current Assets InvestmentsAndOtherCurrentAssets	1096365000	USD
CY2016Q4	dva	Long Term Debt And Other Noncurrent LongTermDebtAndOtherNoncurrent	10221813000	USD
CY2017Q3	dva	Long Term Debt And Other Noncurrent LongTermDebtAndOtherNoncurrent	10142527000	USD
CY2016Q3	dva	Weighted Average Numberof Diluted Shares Contingently Issuable WeightedAverageNumberofDilutedSharesContingentlyIssuable	0	shares
	dva	Weighted Average Numberof Diluted Shares Contingently Issuable WeightedAverageNumberofDilutedSharesContingentlyIssuable	0	shares
CY2017Q3	us-gaap	Allowance For Doubtful Accounts Receivable Current AllowanceForDoubtfulAccountsReceivableCurrent	221329000	USD
CY2017Q3	dva	Longterm Incentive Program Awards Compensation Cost Not Yet Recognized Net LongtermIncentiveProgramAwardsCompensationCostNotYetRecognizedNet	144184000	USD
	dva	Longterm Incentive Program Awards Compensation Cost Not Yet Recognized Period For Recognition LongtermIncentiveProgramAwardsCompensationCostNotYetRecognizedPeriodForRecognition	P1Y1M18D
	dva	Longterm Incentive Program Compensation Cost LongtermIncentiveProgramCompensationCost	61042000	USD
	dva	Longterm Incentive Program Compensation Cost LongtermIncentiveProgramCompensationCost	59481000	USD
CY2016Q4	dva	Medical Expense Payable MedicalExpensePayable	336381000	USD
CY2017Q3	dva	Medical Expense Payable MedicalExpensePayable	400259000	USD
	dva	Other Comprehensive Income Loss Reclassification Adjustment From Aoci For Sale Of Securities Net Of Sold In Current Quarter Net Of Tax OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfSoldInCurrentQuarterNetOfTax	143000	USD
	dva	Other Comprehensive Income Loss Reclassification Adjustment From Aoci For Sale Of Securities Net Of Sold In Current Quarter Net Of Tax OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfSoldInCurrentQuarterNetOfTax	221000	USD
CY2016Q3	dva	Patient Care Costs PatientCareCosts	2697629000	USD
	dva	Patient Care Costs PatientCareCosts	7950987000	USD
CY2017Q3	dva	Patient Care Costs PatientCareCosts	2925975000	USD
	dva	Patient Care Costs PatientCareCosts	8508706000	USD
	dva	Payments For Other Financing Activities PaymentsForOtherFinancingActivities	-709252000	USD
	dva	Payments For Other Financing Activities PaymentsForOtherFinancingActivities	-421369000	USD
	dva	Payments For Proceeds From Sale Of Investments In Securities And Other PaymentsForProceedsFromSaleOfInvestmentsInSecuritiesAndOther	203659000	USD
	dva	Payments For Proceeds From Sale Of Investments In Securities And Other PaymentsForProceedsFromSaleOfInvestmentsInSecuritiesAndOther	-166605000	USD
	dva	Percentage Change In Discount Rate Used To Evaluate Fair Value Of Reporting Unit For Goodwill Assessment PercentageChangeInDiscountRateUsedToEvaluateFairValueOfReportingUnitForGoodwillAssessment	0.01
	dva	Percentage Change In Operating Income Used To Evaluate Fair Value Of Reporting Unit For Goodwill Assessment PercentageChangeInOperatingIncomeUsedToEvaluateFairValueOfReportingUnitForGoodwillAssessment	0.03
CY2017Q3	dva	Percentage Of Outstanding Patient Accounts Receivables PercentageOfOutstandingPatientAccountsReceivables	1
	dva	Proceeds From Repayments Of Long Term Debt ProceedsFromRepaymentsOfLongTermDebt	-98724000	USD
	dva	Proceeds From Repayments Of Long Term Debt ProceedsFromRepaymentsOfLongTermDebt	-108463000	USD
CY2016Q3	dva	Segment Reporting Information Corporate Expenses SegmentReportingInformationCorporateExpenses	28028000	USD
	dva	Segment Reporting Information Corporate Expenses SegmentReportingInformationCorporateExpenses	40366000	USD
CY2017Q3	dva	Segment Reporting Information Corporate Expenses SegmentReportingInformationCorporateExpenses	10965000	USD
	dva	Segment Reporting Information Corporate Expenses SegmentReportingInformationCorporateExpenses	32587000	USD
CY2017Q3	dva	Weighted Average Numberof Diluted Shares Contingently Issuable WeightedAverageNumberofDilutedSharesContingentlyIssuable	2194000	shares
	dva	Weighted Average Numberof Diluted Shares Contingently Issuable WeightedAverageNumberofDilutedSharesContingentlyIssuable	0	shares
CY2016Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	522415000	USD
CY2017Q3	us-gaap	Accounts Payable Current AccountsPayableCurrent	566918000	USD
CY2016Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	1917302000	USD
CY2017Q3	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	2091074000	USD
CY2016Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-89643000	USD
CY2017Q3	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	3476000	USD
	us-gaap	Acquired Finite Lived Intangible Assets Weighted Average Useful Life AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife	P5Y
CY2016Q4	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	1027182000	USD
CY2017Q3	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	1059176000	USD
	us-gaap	Adjustments To Reconcile Net Income Loss To Cash Provided By Used In Operating Activities AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities	636450000	USD
	us-gaap	Adjustments To Reconcile Net Income Loss To Cash Provided By Used In Operating Activities AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities	1074663000	USD
CY2016Q4	us-gaap	Allowance For Doubtful Accounts Receivable Current AllowanceForDoubtfulAccountsReceivableCurrent	252056000	USD
	us-gaap	Allowance For Doubtful Accounts Receivable Period Increase Decrease AllowanceForDoubtfulAccountsReceivablePeriodIncreaseDecrease	-30727000	USD
CY2016Q3	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	2375000	shares
	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	2153000	shares
CY2017Q3	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	8510000	shares
	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	5239000	shares
CY2016Q4	us-gaap	Assets Assets	18741257000	USD
CY2017Q3	us-gaap	Assets Assets	19013339000	USD
CY2016Q4	us-gaap	Assets Current AssetsCurrent	3980228000	USD
CY2017Q3	us-gaap	Assets Current AssetsCurrent	4033549000	USD
CY2016Q4	us-gaap	Available For Sale Securities AvailableForSaleSecurities	107050000	USD
CY2017Q3	us-gaap	Available For Sale Securities AvailableForSaleSecurities	121329000	USD
CY2016Q4	us-gaap	Available For Sale Securities Accumulated Gross Unrealized Gain Loss Before Tax AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainLossBeforeTax	3701000	USD
CY2017Q3	us-gaap	Available For Sale Securities Accumulated Gross Unrealized Gain Loss Before Tax AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainLossBeforeTax	8021000	USD
CY2016Q4	us-gaap	Available For Sale Securities Current AvailableForSaleSecuritiesCurrent	3371000	USD
CY2017Q3	us-gaap	Available For Sale Securities Current AvailableForSaleSecuritiesCurrent	1200000	USD
CY2016Q4	us-gaap	Available For Sale Securities Noncurrent AvailableForSaleSecuritiesNoncurrent	103679000	USD
CY2017Q3	us-gaap	Available For Sale Securities Noncurrent AvailableForSaleSecuritiesNoncurrent	120129000	USD
CY2016Q3	us-gaap	Business Acquisition Pro Forma Earnings Per Share Basic BusinessAcquisitionProFormaEarningsPerShareBasic	2.81
	us-gaap	Business Acquisition Pro Forma Earnings Per Share Basic BusinessAcquisitionProFormaEarningsPerShareBasic	3.57
CY2017Q3	us-gaap	Business Acquisition Pro Forma Earnings Per Share Basic BusinessAcquisitionProFormaEarningsPerShareBasic	-1.13
	us-gaap	Business Acquisition Pro Forma Earnings Per Share Basic BusinessAcquisitionProFormaEarningsPerShareBasic	1.89
CY2016Q3	us-gaap	Business Acquisition Pro Forma Earnings Per Share Diluted BusinessAcquisitionProFormaEarningsPerShareDiluted	2.77
	us-gaap	Business Acquisition Pro Forma Earnings Per Share Diluted BusinessAcquisitionProFormaEarningsPerShareDiluted	3.51
CY2017Q3	us-gaap	Business Acquisition Pro Forma Earnings Per Share Diluted BusinessAcquisitionProFormaEarningsPerShareDiluted	-1.13
	us-gaap	Business Acquisition Pro Forma Earnings Per Share Diluted BusinessAcquisitionProFormaEarningsPerShareDiluted	1.86
CY2016Q3	us-gaap	Business Acquisitions Pro Forma Net Income Loss BusinessAcquisitionsProFormaNetIncomeLoss	572873000	USD
	us-gaap	Business Acquisitions Pro Forma Net Income Loss BusinessAcquisitionsProFormaNetIncomeLoss	728759000	USD
CY2017Q3	us-gaap	Business Acquisitions Pro Forma Net Income Loss BusinessAcquisitionsProFormaNetIncomeLoss	-214156000	USD
	us-gaap	Business Acquisitions Pro Forma Net Income Loss BusinessAcquisitionsProFormaNetIncomeLoss	360679000	USD
CY2016Q3	us-gaap	Business Acquisitions Pro Forma Revenue BusinessAcquisitionsProFormaRevenue	3844174000	USD
	us-gaap	Business Acquisitions Pro Forma Revenue BusinessAcquisitionsProFormaRevenue	11467643000	USD
CY2017Q3	us-gaap	Business Acquisitions Pro Forma Revenue BusinessAcquisitionsProFormaRevenue	3925402000	USD
	us-gaap	Business Acquisitions Pro Forma Revenue BusinessAcquisitionsProFormaRevenue	11638894000	USD
	us-gaap	Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1 BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1	4110000	USD
CY2016Q4	us-gaap	Business Combination Contingent Consideration Liability BusinessCombinationContingentConsiderationLiability	9977000	USD
CY2017Q3	us-gaap	Business Combination Contingent Consideration Liability BusinessCombinationContingentConsiderationLiability	8955000	USD
CY2016Q4	us-gaap	Capital Lease Obligations CapitalLeaseObligations	299682000	USD
CY2017Q3	us-gaap	Capital Lease Obligations CapitalLeaseObligations	330446000	USD
CY2015Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	1499116000	USD
CY2016Q3	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	913496000	USD
CY2016Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	913187000	USD
CY2017Q3	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	846110000	USD
	us-gaap	Cash And Cash Equivalents Period Increase Decrease CashAndCashEquivalentsPeriodIncreaseDecrease	-585620000	USD
	us-gaap	Cash And Cash Equivalents Period Increase Decrease CashAndCashEquivalentsPeriodIncreaseDecrease	-67077000	USD
CY2016Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2017Q3	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2016Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2017Q3	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2016Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	450000000	shares
CY2017Q3	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	450000000	shares
	us-gaap	Consolidation Less Than Wholly Owned Subsidiary Parent Ownership Interest Change Due To Net Income Attributable To Parent And Effects Of Changes Net ConsolidationLessThanWhollyOwnedSubsidiaryParentOwnershipInterestChangeDueToNetIncomeAttributableToParentAndEffectsOfChangesNet	717013000	USD
CY2017Q3	us-gaap	Consolidation Less Than Wholly Owned Subsidiary Parent Ownership Interest Change Due To Net Income Attributable To Parent And Effects Of Changes Net ConsolidationLessThanWhollyOwnedSubsidiaryParentOwnershipInterestChangeDueToNetIncomeAttributableToParentAndEffectsOfChangesNet	-214476000	USD
	us-gaap	Depreciation And Amortization DepreciationAndAmortization	593527000	USD
CY2017Q3	us-gaap	Derivative Fixed Interest Rate DerivativeFixedInterestRate	0.5367
	us-gaap	Consolidation Less Than Wholly Owned Subsidiary Parent Ownership Interest Change Due To Net Income Attributable To Parent And Effects Of Changes Net ConsolidationLessThanWhollyOwnedSubsidiaryParentOwnershipInterestChangeDueToNetIncomeAttributableToParentAndEffectsOfChangesNet	360417000	USD
CY2016Q3	us-gaap	Consolidation Less Than Wholly Owned Subsidiary Parent Ownership Interest Changes Net ConsolidationLessThanWhollyOwnedSubsidiaryParentOwnershipInterestChangesNet	-604000	USD
	us-gaap	Consolidation Less Than Wholly Owned Subsidiary Parent Ownership Interest Changes Net ConsolidationLessThanWhollyOwnedSubsidiaryParentOwnershipInterestChangesNet	-5135000	USD
CY2017Q3	us-gaap	Consolidation Less Than Wholly Owned Subsidiary Parent Ownership Interest Changes Net ConsolidationLessThanWhollyOwnedSubsidiaryParentOwnershipInterestChangesNet	0	USD
	us-gaap	Consolidation Less Than Wholly Owned Subsidiary Parent Ownership Interest Changes Net ConsolidationLessThanWhollyOwnedSubsidiaryParentOwnershipInterestChangesNet	195000	USD
CY2016Q3	us-gaap	Costs And Expenses CostsAndExpenses	2911420000	USD
	us-gaap	Costs And Expenses CostsAndExpenses	9516248000	USD
CY2016Q4	us-gaap	Due From Related Parties Noncurrent DueFromRelatedPartiesNoncurrent	0	USD
CY2016Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	194554491	shares
CY2017Q3	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	194788516	shares
CY2016Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	194554491	shares
CY2017Q3	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	189231693	shares
CY2016Q4	us-gaap	Common Stock Value CommonStockValue	195000	USD
CY2017Q3	us-gaap	Common Stock Value CommonStockValue	195000	USD
CY2016Q3	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	579142000	USD
	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	729748000	USD
CY2017Q3	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-183692000	USD
	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	453341000	USD
CY2016Q3	us-gaap	Comprehensive Income Net Of Tax Attributable To Noncontrolling Interest ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest	40876000	USD
	us-gaap	Comprehensive Income Net Of Tax Attributable To Noncontrolling Interest ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest	122871000	USD
CY2017Q3	us-gaap	Comprehensive Income Net Of Tax Attributable To Noncontrolling Interest ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest	42442000	USD
	us-gaap	Comprehensive Income Net Of Tax Attributable To Noncontrolling Interest ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest	129652000	USD
CY2016Q3	us-gaap	Comprehensive Income Net Of Tax Including Portion Attributable To Noncontrolling Interest ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest	620018000	USD
	us-gaap	Comprehensive Income Net Of Tax Including Portion Attributable To Noncontrolling Interest ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest	852619000	USD
CY2017Q3	us-gaap	Comprehensive Income Net Of Tax Including Portion Attributable To Noncontrolling Interest ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest	-141250000	USD
	us-gaap	Comprehensive Income Net Of Tax Including Portion Attributable To Noncontrolling Interest ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest	582993000	USD
CY2016Q3	us-gaap	Consolidation Less Than Wholly Owned Subsidiary Parent Ownership Interest Change Due To Net Income Attributable To Parent And Effects Of Changes Net ConsolidationLessThanWhollyOwnedSubsidiaryParentOwnershipInterestChangeDueToNetIncomeAttributableToParentAndEffectsOfChangesNet	570728000	USD
CY2017Q3	us-gaap	Costs And Expenses CostsAndExpenses	4115354000	USD
	us-gaap	Costs And Expenses CostsAndExpenses	10423562000	USD
CY2016Q4	us-gaap	Debt Instrument Carrying Amount DebtInstrumentCarryingAmount	9192229000	USD
CY2017Q3	us-gaap	Debt Instrument Carrying Amount DebtInstrumentCarryingAmount	9166430000	USD
CY2017Q3	us-gaap	Debt Instrument Interest Rate During Period DebtInstrumentInterestRateDuringPeriod	0.0477
	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	48778000	USD
	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	-132781000	USD
CY2016Q4	us-gaap	Deferred Tax Liabilities Noncurrent DeferredTaxLiabilitiesNoncurrent	809128000	USD
CY2017Q3	us-gaap	Deferred Tax Liabilities Noncurrent DeferredTaxLiabilitiesNoncurrent	685598000	USD
CY2016Q3	us-gaap	Depreciation And Amortization DepreciationAndAmortization	181739000	USD
	us-gaap	Depreciation And Amortization DepreciationAndAmortization	531475000	USD
CY2017Q3	us-gaap	Depreciation And Amortization DepreciationAndAmortization	203283000	USD
CY2017Q3	us-gaap	Due From Related Parties Noncurrent DueFromRelatedPartiesNoncurrent	0	USD
CY2016Q4	us-gaap	Due To Related Parties Noncurrent DueToRelatedPartiesNoncurrent	0	USD
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	1.89
CY2017Q3	us-gaap	Due To Related Parties Noncurrent DueToRelatedPartiesNoncurrent	0	USD
CY2016Q3	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	2.80
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	3.54
CY2017Q3	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-1.14
CY2016Q3	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	2.76
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	3.48
CY2017Q3	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-1.14
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	1.86
	us-gaap	Effect Of Exchange Rate On Cash And Cash Equivalents EffectOfExchangeRateOnCashAndCashEquivalents	-1664000	USD
	us-gaap	Effect Of Exchange Rate On Cash And Cash Equivalents EffectOfExchangeRateOnCashAndCashEquivalents	5449000	USD
CY2016Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	815761000	USD
CY2017Q3	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	775280000	USD
CY2017Q3	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized	82765000	USD
	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1 EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1	P1Y6M
	us-gaap	Employee Service Share Based Compensation Tax Benefit Realized From Exercise Of Stock Options EmployeeServiceShareBasedCompensationTaxBenefitRealizedFromExerciseOfStockOptions	27012000	USD
	us-gaap	Employee Service Share Based Compensation Tax Benefit Realized From Exercise Of Stock Options EmployeeServiceShareBasedCompensationTaxBenefitRealizedFromExerciseOfStockOptions	6046000	USD
	us-gaap	Equity Method Investment Dividends Or Distributions EquityMethodInvestmentDividendsOrDistributions	0	USD
	us-gaap	Equity Method Investment Dividends Or Distributions EquityMethodInvestmentDividendsOrDistributions	80000	USD
CY2016Q4	us-gaap	Equity Method Investments EquityMethodInvestments	0	USD
CY2017Q3	us-gaap	Equity Method Investments EquityMethodInvestments	0	USD
CY2016Q4	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	940731000	USD
CY2017Q3	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	1084682000	USD
CY2016Q3	us-gaap	Gain Loss On Sale Of Business GainLossOnSaleOfBusiness	374374000	USD
	us-gaap	Gain Loss On Sale Of Business GainLossOnSaleOfBusiness	404165000	USD
CY2017Q3	us-gaap	Gain Loss On Sale Of Business GainLossOnSaleOfBusiness	17129000	USD
	us-gaap	Gain Loss On Sale Of Business GainLossOnSaleOfBusiness	23402000	USD
CY2016Q3	us-gaap	Gain Loss Related To Litigation Settlement GainLossRelatedToLitigationSettlement	0	USD
	us-gaap	Gain Loss Related To Litigation Settlement GainLossRelatedToLitigationSettlement	0	USD
CY2017Q3	us-gaap	Gain Loss Related To Litigation Settlement GainLossRelatedToLitigationSettlement	0	USD
	us-gaap	Gain Loss Related To Litigation Settlement GainLossRelatedToLitigationSettlement	526827000	USD
CY2016Q3	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	406890000	USD
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	1180214000	USD
CY2017Q3	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	400018000	USD
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	1174113000	USD
CY2015Q4	us-gaap	Goodwill Goodwill	9294479000	USD
CY2016Q4	us-gaap	Goodwill Goodwill	9407317000	USD
CY2017Q3	us-gaap	Goodwill Goodwill	9415877000	USD
CY2016	us-gaap	Goodwill Acquired During Period GoodwillAcquiredDuringPeriod	447828000	USD
	us-gaap	Goodwill Acquired During Period GoodwillAcquiredDuringPeriod	687875000	USD
CY2016	us-gaap	Goodwill Foreign Currency Translation Gain Loss GoodwillForeignCurrencyTranslationGainLoss	-8816000	USD
	us-gaap	Goodwill Foreign Currency Translation Gain Loss GoodwillForeignCurrencyTranslationGainLoss	39383000	USD
CY2017Q3	us-gaap	Goodwill Gross GoodwillGross	10578325000	USD
CY2017Q3	us-gaap	Goodwill Impaired Accumulated Impairment Loss GoodwillImpairedAccumulatedImpairmentLoss	1162448000	USD
CY2016Q3	us-gaap	Goodwill Impairment Loss GoodwillImpairmentLoss	0	USD
	us-gaap	Goodwill Impairment Loss GoodwillImpairmentLoss	253000000	USD
	us-gaap	Health Care Organization Patient Service Revenue Provisionfor Bad Debts HealthCareOrganizationPatientServiceRevenueProvisionforBadDebts	336188000	USD
CY2017Q3	us-gaap	Health Care Organization Patient Service Revenue Provisionfor Bad Debts HealthCareOrganizationPatientServiceRevenueProvisionforBadDebts	123760000	USD
	us-gaap	Health Care Organization Patient Service Revenue Provisionfor Bad Debts HealthCareOrganizationPatientServiceRevenueProvisionforBadDebts	352228000	USD
CY2016Q3	us-gaap	Health Care Organization Revenue HealthCareOrganizationRevenue	3730576000	USD
	us-gaap	Health Care Organization Revenue HealthCareOrganizationRevenue	11029363000	USD
CY2017Q3	us-gaap	Health Care Organization Revenue HealthCareOrganizationRevenue	3922831000	USD
	us-gaap	Income Loss From Equity Method Investments IncomeLossFromEquityMethodInvestments	5119000	USD
CY2017Q3	us-gaap	Income Loss From Equity Method Investments IncomeLossFromEquityMethodInvestments	-4852000	USD
	us-gaap	Income Loss From Equity Method Investments IncomeLossFromEquityMethodInvestments	2697000	USD
CY2016Q3	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	104301000	USD
	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	366011000	USD
CY2016	us-gaap	Goodwill Impairment Loss GoodwillImpairmentLoss	281415000	USD
CY2017Q3	us-gaap	Goodwill Impairment Loss GoodwillImpairmentLoss	601040000	USD
	us-gaap	Goodwill Impairment Loss GoodwillImpairmentLoss	686355000	USD
CY2016	us-gaap	Goodwill Written Off Related To Sale Of Business Unit GoodwillWrittenOffRelatedToSaleOfBusinessUnit	44759000	USD
	us-gaap	Goodwill Written Off Related To Sale Of Business Unit GoodwillWrittenOffRelatedToSaleOfBusinessUnit	32343000	USD
CY2016Q3	us-gaap	Health Care Organization Capitation Revenue HealthCareOrganizationCapitationRevenue	872538000	USD
	us-gaap	Health Care Organization Capitation Revenue HealthCareOrganizationCapitationRevenue	2660532000	USD
CY2017Q3	us-gaap	Health Care Organization Capitation Revenue HealthCareOrganizationCapitationRevenue	1016365000	USD
	us-gaap	Health Care Organization Capitation Revenue HealthCareOrganizationCapitationRevenue	2956479000	USD
CY2016Q3	us-gaap	Health Care Organization Other Revenue HealthCareOrganizationOtherRevenue	330399000	USD
	us-gaap	Health Care Organization Other Revenue HealthCareOrganizationOtherRevenue	996378000	USD
CY2017Q3	us-gaap	Health Care Organization Other Revenue HealthCareOrganizationOtherRevenue	283969000	USD
	us-gaap	Health Care Organization Other Revenue HealthCareOrganizationOtherRevenue	863238000	USD
CY2016Q3	us-gaap	Health Care Organization Patient Service Revenue HealthCareOrganizationPatientServiceRevenue	2643194000	USD
	us-gaap	Health Care Organization Patient Service Revenue HealthCareOrganizationPatientServiceRevenue	7708641000	USD
CY2017Q3	us-gaap	Health Care Organization Patient Service Revenue HealthCareOrganizationPatientServiceRevenue	2746257000	USD
	us-gaap	Health Care Organization Patient Service Revenue HealthCareOrganizationPatientServiceRevenue	8030102000	USD
CY2016Q3	us-gaap	Health Care Organization Patient Service Revenue Less Provision For Bad Debts HealthCareOrganizationPatientServiceRevenueLessProvisionForBadDebts	2527639000	USD
	us-gaap	Health Care Organization Patient Service Revenue Less Provision For Bad Debts HealthCareOrganizationPatientServiceRevenueLessProvisionForBadDebts	7372453000	USD
CY2017Q3	us-gaap	Health Care Organization Patient Service Revenue Less Provision For Bad Debts HealthCareOrganizationPatientServiceRevenueLessProvisionForBadDebts	2622497000	USD
	us-gaap	Health Care Organization Patient Service Revenue Less Provision For Bad Debts HealthCareOrganizationPatientServiceRevenueLessProvisionForBadDebts	7677874000	USD
CY2016Q3	us-gaap	Health Care Organization Patient Service Revenue Provisionfor Bad Debts HealthCareOrganizationPatientServiceRevenueProvisionforBadDebts	115555000	USD
	us-gaap	Health Care Organization Revenue HealthCareOrganizationRevenue	11497591000	USD
CY2016Q4	us-gaap	Held To Maturity Securities HeldToMaturitySecurities	306827000	USD
CY2017Q3	us-gaap	Held To Maturity Securities HeldToMaturitySecurities	136158000	USD
CY2016Q4	us-gaap	Held To Maturity Securities Current HeldToMaturitySecuritiesCurrent	306827000	USD
CY2017Q3	us-gaap	Held To Maturity Securities Current HeldToMaturitySecuritiesCurrent	136158000	USD
CY2016Q4	us-gaap	Held To Maturity Securities Noncurrent HeldToMaturitySecuritiesNoncurrent	0	USD
CY2017Q3	us-gaap	Held To Maturity Securities Noncurrent HeldToMaturitySecuritiesNoncurrent	0	USD
CY2016Q3	us-gaap	Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments	716451000	USD
	us-gaap	Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments	1210823000	USD
CY2017Q3	us-gaap	Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments	-297776000	USD
	us-gaap	Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments	765881000	USD
CY2016Q3	us-gaap	Income Loss From Equity Method Investments IncomeLossFromEquityMethodInvestments	4237000	USD
CY2016Q4	us-gaap	Liabilities Current LiabilitiesCurrent	2696445000	USD
CY2017Q3	us-gaap	Liabilities Current LiabilitiesCurrent	2874793000	USD
CY2016Q4	us-gaap	Long Term Debt And Capital Lease Obligations LongTermDebtAndCapitalLeaseObligations	8947327000	USD
CY2016Q3	us-gaap	Interest And Debt Expense InterestAndDebtExpense	104581000	USD
	us-gaap	Interest And Debt Expense InterestAndDebtExpense	310359000	USD
CY2017Q3	us-gaap	Interest And Debt Expense InterestAndDebtExpense	109623000	USD
	us-gaap	Interest And Debt Expense InterestAndDebtExpense	322014000	USD
CY2016Q4	us-gaap	Inventory Net InventoryNet	164858000	USD
CY2017Q3	us-gaap	Long Term Debt And Capital Lease Obligations LongTermDebtAndCapitalLeaseObligations	8908703000	USD
CY2016Q4	us-gaap	Long Term Debt And Capital Lease Obligations Current LongTermDebtAndCapitalLeaseObligationsCurrent	165041000	USD
CY2017Q3	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-125742000	USD
	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	276005000	USD
CY2016Q4	us-gaap	Income Taxes Receivable IncomeTaxesReceivable	10596000	USD
CY2017Q3	us-gaap	Income Taxes Receivable IncomeTaxesReceivable	0	USD
	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	-45507000	USD
	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	18595000	USD
	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	85660000	USD
	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	146024000	USD
	us-gaap	Increase Decrease In Accrued Income Taxes Payable IncreaseDecreaseInAccruedIncomeTaxesPayable	79592000	USD
	us-gaap	Increase Decrease In Accrued Income Taxes Payable IncreaseDecreaseInAccruedIncomeTaxesPayable	22669000	USD
	us-gaap	Increase Decrease In Employee Related Liabilities IncreaseDecreaseInEmployeeRelatedLiabilities	79289000	USD
	us-gaap	Increase Decrease In Employee Related Liabilities IncreaseDecreaseInEmployeeRelatedLiabilities	-60063000	USD
	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	13045000	USD
	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	-14272000	USD
	us-gaap	Increase Decrease In Other Current Liabilities IncreaseDecreaseInOtherCurrentLiabilities	119549000	USD
	us-gaap	Increase Decrease In Other Current Liabilities IncreaseDecreaseInOtherCurrentLiabilities	39445000	USD
	us-gaap	Increase Decrease In Other Noncurrent Assets IncreaseDecreaseInOtherNoncurrentAssets	-31081000	USD
	us-gaap	Increase Decrease In Other Noncurrent Assets IncreaseDecreaseInOtherNoncurrentAssets	13831000	USD
	us-gaap	Increase Decrease In Other Noncurrent Liabilities IncreaseDecreaseInOtherNoncurrentLiabilities	-12126000	USD
	us-gaap	Increase Decrease In Other Noncurrent Liabilities IncreaseDecreaseInOtherNoncurrentLiabilities	18648000	USD
CY2016Q3	us-gaap	Incremental Common Shares Attributable To Share Based Payment Arrangements IncrementalCommonSharesAttributableToShareBasedPaymentArrangements	1006000	shares
	us-gaap	Incremental Common Shares Attributable To Share Based Payment Arrangements IncrementalCommonSharesAttributableToShareBasedPaymentArrangements	1243000	shares
CY2017Q3	us-gaap	Incremental Common Shares Attributable To Share Based Payment Arrangements IncrementalCommonSharesAttributableToShareBasedPaymentArrangements	0	shares
	us-gaap	Incremental Common Shares Attributable To Share Based Payment Arrangements IncrementalCommonSharesAttributableToShareBasedPaymentArrangements	582000	shares
CY2016Q4	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	1527767000	USD
CY2017Q3	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	1451033000	USD
CY2017Q3	us-gaap	Inventory Net InventoryNet	154422000	USD
CY2016Q4	us-gaap	Investments And Other Noncurrent Assets InvestmentsAndOtherNoncurrentAssets	650578000	USD
CY2017Q3	us-gaap	Investments And Other Noncurrent Assets InvestmentsAndOtherNoncurrentAssets	726824000	USD
CY2016Q4	us-gaap	Investments In Affiliates Subsidiaries Associates And Joint Ventures InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures	502389000	USD
CY2017Q3	us-gaap	Investments In Affiliates Subsidiaries Associates And Joint Ventures InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures	545053000	USD
CY2016Q4	us-gaap	Liabilities Liabilities	12918258000	USD
CY2017Q3	us-gaap	Liabilities Liabilities	13017320000	USD
CY2016Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	18741257000	USD
CY2017Q3	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	19013339000	USD
CY2017Q3	us-gaap	Long Term Debt And Capital Lease Obligations Current LongTermDebtAndCapitalLeaseObligationsCurrent	189822000	USD
CY2016Q4	us-gaap	Long Term Debt And Capital Lease Obligations Including Current Maturities LongTermDebtAndCapitalLeaseObligationsIncludingCurrentMaturities	9112368000	USD
CY2017Q3	us-gaap	Long Term Debt And Capital Lease Obligations Including Current Maturities LongTermDebtAndCapitalLeaseObligationsIncludingCurrentMaturities	9098525000	USD
CY2017Q3	us-gaap	Long Term Debt Maturities Repayments Of Principal After Year Five LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive	3526815000	USD
CY2017Q3	us-gaap	Long Term Debt Maturities Repayments Of Principal In Next Twelve Months LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths	171825000	USD
CY2017Q3	us-gaap	Long Term Debt Maturities Repayments Of Principal In Year Five LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive	1282115000	USD
CY2017Q3	us-gaap	Long Term Debt Maturities Repayments Of Principal In Year Four LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour	3305940000	USD
CY2017Q3	us-gaap	Long Term Debt Maturities Repayments Of Principal In Year Three LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree	72346000	USD
CY2017Q3	us-gaap	Long Term Debt Maturities Repayments Of Principal In Year Two LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo	747908000	USD
CY2017Q3	us-gaap	Long Term Debt Maturities Repayments Of Principal Remainder Of Fiscal Year LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear	59481000	USD
CY2016Q4	us-gaap	Long Term Investments LongTermInvestments	103679000	USD
CY2017Q3	us-gaap	Long Term Investments LongTermInvestments	120129000	USD
CY2017Q3	us-gaap	Longterm Debt Weighted Average Interest Rate LongtermDebtWeightedAverageInterestRate	0.0478
CY2016Q4	us-gaap	Loss Contingency Accrual At Carrying Value LossContingencyAccrualAtCarryingValue	69000000	USD
CY2017Q3	us-gaap	Loss Contingency Accrual At Carrying Value LossContingencyAccrualAtCarryingValue	51000000	USD
CY2016Q4	us-gaap	Marketable Securities MarketableSecurities	413877000	USD
CY2017Q3	us-gaap	Marketable Securities MarketableSecurities	257487000	USD
CY2016Q4	us-gaap	Marketable Securities Current MarketableSecuritiesCurrent	310198000	USD
CY2017Q3	us-gaap	Marketable Securities Current MarketableSecuritiesCurrent	137358000	USD
CY2016Q4	us-gaap	Marketable Securities Noncurrent MarketableSecuritiesNoncurrent	103679000	USD
CY2017Q3	us-gaap	Marketable Securities Noncurrent MarketableSecuritiesNoncurrent	120129000	USD
CY2016Q4	us-gaap	Minority Interest MinorityInterest	201694000	USD
CY2017Q3	us-gaap	Minority Interest MinorityInterest	184548000	USD
	us-gaap	Net Cash Provided By Used In Financing Activities Continuing Operations NetCashProvidedByUsedInFinancingActivitiesContinuingOperations	-807976000	USD
	us-gaap	Net Cash Provided By Used In Financing Activities Continuing Operations NetCashProvidedByUsedInFinancingActivitiesContinuingOperations	-529832000	USD
	us-gaap	Net Cash Provided By Used In Investing Activities Continuing Operations NetCashProvidedByUsedInInvestingActivitiesContinuingOperations	-1257242000	USD
	us-gaap	Net Cash Provided By Used In Investing Activities Continuing Operations NetCashProvidedByUsedInInvestingActivitiesContinuingOperations	-1107233000	USD
	us-gaap	Net Cash Provided By Used In Operating Activities Continuing Operations NetCashProvidedByUsedInOperatingActivitiesContinuingOperations	1481262000	USD
	us-gaap	Net Cash Provided By Used In Operating Activities Continuing Operations NetCashProvidedByUsedInOperatingActivitiesContinuingOperations	1564539000	USD
CY2016Q3	us-gaap	Net Income Loss NetIncomeLoss	571332000	USD
	us-gaap	Net Income Loss NetIncomeLoss	722148000	USD
CY2017Q3	us-gaap	Net Income Loss NetIncomeLoss	-214476000	USD
	us-gaap	Net Income Loss NetIncomeLoss	360222000	USD
CY2016Q3	us-gaap	Net Income Loss Attributable To Noncontrolling Interest NetIncomeLossAttributableToNoncontrollingInterest	40818000	USD
	us-gaap	Net Income Loss Attributable To Noncontrolling Interest NetIncomeLossAttributableToNoncontrollingInterest	122664000	USD
CY2017Q3	us-gaap	Net Income Loss Attributable To Noncontrolling Interest NetIncomeLossAttributableToNoncontrollingInterest	42442000	USD
	us-gaap	Net Income Loss Attributable To Noncontrolling Interest NetIncomeLossAttributableToNoncontrollingInterest	129654000	USD
	us-gaap	Number Of Operating Segments NumberOfOperatingSegments	2	Segment
CY2016Q3	us-gaap	Operating Income Loss OperatingIncomeLoss	819156000	USD
	us-gaap	Operating Income Loss OperatingIncomeLoss	1513115000	USD
CY2017Q3	us-gaap	Operating Income Loss OperatingIncomeLoss	-192523000	USD
	us-gaap	Operating Income Loss OperatingIncomeLoss	1074029000	USD
CY2016Q4	us-gaap	Other Assets Current OtherAssetsCurrent	210604000	USD
CY2017Q3	us-gaap	Other Assets Current OtherAssetsCurrent	205211000	USD
CY2016Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	44510000	USD
CY2017Q3	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	61642000	USD
CY2016Q3	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Gain Loss Arising During Period Net Of Tax OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax	-951000	USD
	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Gain Loss Arising During Period Net Of Tax OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax	5386000	USD
CY2017Q3	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Gain Loss Arising During Period Net Of Tax OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax	29143000	USD
	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Gain Loss Arising During Period Net Of Tax OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax	91546000	USD
CY2016Q3	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Reclassification Adjustment From Aoci Realized Upon Sale Or Liquidation Net Of Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationReclassificationAdjustmentFromAOCIRealizedUponSaleOrLiquidationNetOfTax	-7513000	USD
	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Reclassification Adjustment From Aoci Realized Upon Sale Or Liquidation Net Of Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationReclassificationAdjustmentFromAOCIRealizedUponSaleOrLiquidationNetOfTax	-7513000	USD
CY2017Q3	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Reclassification Adjustment From Aoci Realized Upon Sale Or Liquidation Net Of Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationReclassificationAdjustmentFromAOCIRealizedUponSaleOrLiquidationNetOfTax	0	USD
	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Reclassification Adjustment From Aoci Realized Upon Sale Or Liquidation Net Of Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationReclassificationAdjustmentFromAOCIRealizedUponSaleOrLiquidationNetOfTax	0	USD
CY2016Q3	us-gaap	Other Comprehensive Income Loss Net Of Tax OtherComprehensiveIncomeLossNetOfTax	7868000	USD
	us-gaap	Other Comprehensive Income Loss Net Of Tax OtherComprehensiveIncomeLossNetOfTax	7807000	USD
CY2017Q3	us-gaap	Other Comprehensive Income Loss Net Of Tax OtherComprehensiveIncomeLossNetOfTax	30784000	USD
	us-gaap	Other Comprehensive Income Loss Net Of Tax OtherComprehensiveIncomeLossNetOfTax	93117000	USD
	us-gaap	Other Comprehensive Income Loss Reclassification Adjustment From Aoci For Sale Of Securities Before Tax OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesBeforeTax	233000	USD
	us-gaap	Other Comprehensive Income Loss Reclassification Adjustment From Aoci For Sale Of Securities Before Tax OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesBeforeTax	362000	USD
CY2016Q3	us-gaap	Other Comprehensive Income Loss Reclassification Adjustment From Aoci For Sale Of Securities Net Of Tax OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax	50000	USD
	us-gaap	Other Comprehensive Income Loss Reclassification Adjustment From Aoci For Sale Of Securities Net Of Tax OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax	143000	USD
CY2017Q3	us-gaap	Other Comprehensive Income Loss Reclassification Adjustment From Aoci For Sale Of Securities Net Of Tax OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax	9000	USD
	us-gaap	Other Comprehensive Income Loss Reclassification Adjustment From Aoci For Sale Of Securities Net Of Tax OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax	221000	USD
CY2016Q3	us-gaap	Other Comprehensive Income Loss Reclassification Adjustment From Aoci On Derivatives Net Of Tax OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIOnDerivativesNetOfTax	-388000	USD
	us-gaap	Other Comprehensive Income Loss Reclassification Adjustment From Aoci On Derivatives Net Of Tax OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIOnDerivativesNetOfTax	-1301000	USD
CY2017Q3	us-gaap	Other Comprehensive Income Loss Reclassification Adjustment From Aoci On Derivatives Net Of Tax OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIOnDerivativesNetOfTax	-1265000	USD
	us-gaap	Other Comprehensive Income Loss Reclassification Adjustment From Aoci On Derivatives Net Of Tax OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIOnDerivativesNetOfTax	-3793000	USD
CY2016Q3	us-gaap	Other Comprehensive Income Unrealized Gain Loss On Derivatives Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedGainLossOnDerivativesArisingDuringPeriodNetOfTax	-153000	USD
	us-gaap	Other Comprehensive Income Unrealized Gain Loss On Derivatives Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedGainLossOnDerivativesArisingDuringPeriodNetOfTax	-8238000	USD
CY2017Q3	us-gaap	Other Comprehensive Income Unrealized Gain Loss On Derivatives Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedGainLossOnDerivativesArisingDuringPeriodNetOfTax	-478000	USD
	us-gaap	Other Comprehensive Income Unrealized Gain Loss On Derivatives Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedGainLossOnDerivativesArisingDuringPeriodNetOfTax	-5479000	USD
CY2016Q3	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	1121000	USD
	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	1988000	USD
CY2017Q3	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	863000	USD
	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	3478000	USD
CY2016Q4	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent	856847000	USD
CY2017Q3	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent	928123000	USD
CY2016Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	465358000	USD
CY2017Q3	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	548226000	USD
	us-gaap	Other Noncash Expense OtherNoncashExpense	9163000	USD
	us-gaap	Other Noncash Expense OtherNoncashExpense	41709000	USD
CY2016Q3	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	1876000	USD
	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	8067000	USD
CY2017Q3	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	4370000	USD
	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	13866000	USD
CY2016Q4	us-gaap	Other Receivables Net Current OtherReceivablesNetCurrent	453483000	USD
CY2017Q3	us-gaap	Other Receivables Net Current OtherReceivablesNetCurrent	599374000	USD
	us-gaap	Payments For Proceeds From Businesses And Interest In Affiliates PaymentsForProceedsFromBusinessesAndInterestInAffiliates	726538000	USD
	us-gaap	Payments For Repurchase Of Common Stock PaymentsForRepurchaseOfCommonStock	620898000	USD
	us-gaap	Payments For Repurchase Of Common Stock PaymentsForRepurchaseOfCommonStock	321411000	USD
	us-gaap	Payments Of Distributions To Affiliates PaymentsOfDistributionsToAffiliates	145072000	USD
	us-gaap	Payments Of Distributions To Affiliates PaymentsOfDistributionsToAffiliates	165463000	USD
	us-gaap	Payments To Acquire Available For Sale Securities PaymentsToAcquireAvailableForSaleSecurities	9041000	USD
	us-gaap	Payments To Acquire Available For Sale Securities PaymentsToAcquireAvailableForSaleSecurities	9882000	USD
	us-gaap	Payments To Acquire Businesses Gross PaymentsToAcquireBusinessesGross	497331000	USD
	us-gaap	Payments To Acquire Businesses Gross PaymentsToAcquireBusinessesGross	726538000	USD
	us-gaap	Proceeds From Sale Of Available For Sale Securities ProceedsFromSaleOfAvailableForSaleSecurities	5822000	USD
	us-gaap	Proceeds From Sale Of Available For Sale Securities Debt ProceedsFromSaleOfAvailableForSaleSecuritiesDebt	5822000	USD
	us-gaap	Payments To Acquire Equity Method Investments PaymentsToAcquireEquityMethodInvestments	11629000	USD
	us-gaap	Payments To Acquire Equity Method Investments PaymentsToAcquireEquityMethodInvestments	3014000	USD
	us-gaap	Payments To Acquire Held To Maturity Securities PaymentsToAcquireHeldToMaturitySecurities	976411000	USD
	us-gaap	Payments To Acquire Held To Maturity Securities PaymentsToAcquireHeldToMaturitySecurities	225166000	USD
	us-gaap	Payments To Acquire Intangible Assets PaymentsToAcquireIntangibleAssets	75000	USD
	us-gaap	Payments To Acquire Intangible Assets PaymentsToAcquireIntangibleAssets	0	USD
CY2016Q3	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	216616000	USD
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	575243000	USD
CY2017Q3	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	240889000	USD
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	639829000	USD
	us-gaap	Payments To Minority Shareholders PaymentsToMinorityShareholders	9727000	USD
	us-gaap	Payments To Minority Shareholders PaymentsToMinorityShareholders	1432000	USD
CY2016Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2017Q3	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2016Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	5000000	shares
CY2017Q3	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	5000000	shares
CY2016Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2017Q3	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2016Q4	us-gaap	Preferred Stock Value PreferredStockValue		USD
CY2017Q3	us-gaap	Preferred Stock Value PreferredStockValue		USD
	us-gaap	Proceeds From Contributions From Affiliates ProceedsFromContributionsFromAffiliates	35524000	USD
	us-gaap	Proceeds From Contributions From Affiliates ProceedsFromContributionsFromAffiliates	51156000	USD
	us-gaap	Proceeds From Issuance Of Long Term Debt ProceedsFromIssuanceOfLongTermDebt	39102302000	USD
	us-gaap	Proceeds From Issuance Of Long Term Debt ProceedsFromIssuanceOfLongTermDebt	38160821000	USD
	us-gaap	Proceeds From Payments For Other Financing Activities ProceedsFromPaymentsForOtherFinancingActivities	12584000	USD
	us-gaap	Proceeds From Payments For Other Financing Activities ProceedsFromPaymentsForOtherFinancingActivities	0	USD
	us-gaap	Proceeds From Repayments Of Related Party Debt ProceedsFromRepaymentsOfRelatedPartyDebt	0	USD
	us-gaap	Proceeds From Repayments Of Related Party Debt ProceedsFromRepaymentsOfRelatedPartyDebt	0	USD
	us-gaap	Proceeds From Sale And Maturity Of Held To Maturity Securities ProceedsFromSaleAndMaturityOfHeldToMaturitySecurities	743941000	USD
	us-gaap	Proceeds From Sale And Maturity Of Held To Maturity Securities ProceedsFromSaleAndMaturityOfHeldToMaturitySecurities	398765000	USD
	us-gaap	Proceeds From Sale Of Available For Sale Securities ProceedsFromSaleOfAvailableForSaleSecurities	8636000	USD
CY2017Q3	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	3386056000	USD
CY2016Q4	us-gaap	Property Plant And Equipment Owned Accumulated Depreciation PropertyPlantAndEquipmentOwnedAccumulatedDepreciation	2832160000	USD
	us-gaap	Proceeds From Sale Of Available For Sale Securities Equity ProceedsFromSaleOfAvailableForSaleSecuritiesEquity	4645000	USD
	us-gaap	Proceeds From Sale Of Equity Method Investments ProceedsFromSaleOfEquityMethodInvestments	40920000	USD
	us-gaap	Proceeds From Sale Of Equity Method Investments ProceedsFromSaleOfEquityMethodInvestments	0	USD
	us-gaap	Proceeds From Sales Of Business Affiliate And Productive Assets ProceedsFromSalesOfBusinessAffiliateAndProductiveAssets	18991000	USD
	us-gaap	Proceeds From Sales Of Business Affiliate And Productive Assets ProceedsFromSalesOfBusinessAffiliateAndProductiveAssets	92529000	USD
	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	18515000	USD
	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	15781000	USD
CY2016Q3	us-gaap	Profit Loss ProfitLoss	612150000	USD
	us-gaap	Profit Loss ProfitLoss	844812000	USD
CY2017Q3	us-gaap	Profit Loss ProfitLoss	-172034000	USD
	us-gaap	Profit Loss ProfitLoss	489876000	USD
CY2016Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	3175367000	USD
CY2016Q3	us-gaap	Provision For Doubtful Accounts ProvisionForDoubtfulAccounts	3773000	USD
	us-gaap	Provision For Doubtful Accounts ProvisionForDoubtfulAccounts	9856000	USD
CY2017Q3	us-gaap	Provision For Doubtful Accounts ProvisionForDoubtfulAccounts	-2685000	USD
	us-gaap	Provision For Doubtful Accounts ProvisionForDoubtfulAccounts	-1381000	USD
CY2017Q3	us-gaap	Property Plant And Equipment Owned Accumulated Depreciation PropertyPlantAndEquipmentOwnedAccumulatedDepreciation	3151402000	USD
CY2016Q4	us-gaap	Redeemable Noncontrolling Interest Equity Carrying Amount RedeemableNoncontrollingInterestEquityCarryingAmount	973258000	USD
CY2017Q3	us-gaap	Redeemable Noncontrolling Interest Equity Carrying Amount RedeemableNoncontrollingInterestEquityCarryingAmount	1026890000	USD
CY2017Q3	us-gaap	Related Party Transaction Due From To Related Party Noncurrent RelatedPartyTransactionDueFromToRelatedPartyNoncurrent	0	USD
	us-gaap	Repayments Of Debt And Capital Lease Obligations RepaymentsOfDebtAndCapitalLeaseObligations	39201204000	USD
	us-gaap	Repayments Of Debt And Capital Lease Obligations RepaymentsOfDebtAndCapitalLeaseObligations	38269284000	USD
CY2016Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	3710313000	USD
CY2017Q3	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	4070535000	USD
CY2016Q4	us-gaap	Senior Notes SeniorNotes	4500000000	USD
CY2017Q3	us-gaap	Senior Notes SeniorNotes	4500000000	USD
	us-gaap	Share Based Compensation ShareBasedCompensation	29817000	USD
	us-gaap	Share Based Compensation ShareBasedCompensation	28478000	USD
CY2017Q3	us-gaap	Stock Repurchase Program Number Of Shares Authorized To Be Repurchased StockRepurchaseProgramNumberOfSharesAuthorizedToBeRepurchased	247039000	shares
CY2016Q4	us-gaap	Stockholders Equity StockholdersEquity	4648047000	USD
CY2017Q3	us-gaap	Stockholders Equity StockholdersEquity	4784581000	USD
CY2016Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	4849741000	USD
CY2017Q3	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	4969129000	USD
CY2016Q4	us-gaap	Taxes Payable Current TaxesPayableCurrent	0	USD
CY2017Q3	us-gaap	Taxes Payable Current TaxesPayableCurrent	14391000	USD
	us-gaap	Treasury Stock Acquired Average Cost Per Share TreasuryStockAcquiredAverageCostPerShare	62.77
CY2016Q4	us-gaap	Treasury Stock Common Shares TreasuryStockCommonShares	0	shares
CY2017Q3	us-gaap	Treasury Stock Common Shares TreasuryStockCommonShares	5556823	shares
	us-gaap	Treasury Stock Shares Acquired TreasuryStockSharesAcquired	5557000	shares
CY2016Q4	us-gaap	Treasury Stock Value TreasuryStockValue	0	USD
CY2017Q3	us-gaap	Treasury Stock Value TreasuryStockValue	348801000	USD
	us-gaap	Treasury Stock Value Acquired Cost Method TreasuryStockValueAcquiredCostMethod	348801000	USD
CY2016Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	24066000	USD
CY2017Q3	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	27196000	USD
CY2016Q4	us-gaap	Unrecognized Tax Benefits Income Tax Penalties And Interest Accrued UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued	2595000	USD
CY2017Q3	us-gaap	Unrecognized Tax Benefits Income Tax Penalties And Interest Accrued UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued	3838000	USD
	us-gaap	Unrecognized Tax Benefits Period Increase Decrease UnrecognizedTaxBenefitsPeriodIncreaseDecrease	3130000	USD
CY2017Q3	us-gaap	Variable Interest Entity Consolidated Carrying Amount Assets VariableInterestEntityConsolidatedCarryingAmountAssets	840164000	USD
CY2017Q3	us-gaap	Variable Interest Entity Consolidated Carrying Amount Liabilities VariableInterestEntityConsolidatedCarryingAmountLiabilities	436994000	USD
CY2016Q3	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	206961450	shares
CY2016Q3	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	206961000	shares
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	207643794	shares
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	207644000	shares
CY2017Q3	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	188884000	shares
CY2017Q3	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	188883922	shares
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	193546245	shares
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	193546000	shares
CY2016Q3	us-gaap	Weighted Average Number Of Shares Contingently Issuable WeightedAverageNumberOfSharesContingentlyIssuable	2194000	shares
	us-gaap	Weighted Average Number Of Shares Contingently Issuable WeightedAverageNumberOfSharesContingentlyIssuable	2194000	shares
CY2017Q3	us-gaap	Weighted Average Number Of Shares Contingently Issuable WeightedAverageNumberOfSharesContingentlyIssuable	2194000	shares
	us-gaap	Weighted Average Number Of Shares Contingently Issuable WeightedAverageNumberOfSharesContingentlyIssuable	2194000	shares
CY2016Q3	us-gaap	Weighted Average Number Of Shares Issued Basic WeightedAverageNumberOfSharesIssuedBasic	205955000	shares
	us-gaap	Weighted Average Number Of Shares Issued Basic WeightedAverageNumberOfSharesIssuedBasic	206401000	shares
CY2017Q3	us-gaap	Weighted Average Number Of Shares Issued Basic WeightedAverageNumberOfSharesIssuedBasic	191078000	shares
	us-gaap	Weighted Average Number Of Shares Issued Basic WeightedAverageNumberOfSharesIssuedBasic	192964000	shares
CY2016Q3	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	203761000	shares
CY2016Q3	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	203761433	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	204206979	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	204207000	shares
CY2017Q3	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	188883922	shares
CY2017Q3	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	188884000	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	190770165	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	190770000	shares
	us-gaap	Description Of New Accounting Pronouncements Not Yet Adopted DescriptionOfNewAccountingPronouncementsNotYetAdopted	<div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">New accounting standards</font></div><div style="line-height:120%;padding-top:13px;text-align:left;text-indent:36px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In May 2014, the FASB issued ASU No. 2014-09, </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">Revenue from Contracts with Customers</font><font style="font-family:inherit;font-size:10pt;">, which requires an entity to recognize the amount of revenue to which it expects to be entitled for the transfer of promised goods or services to customers. In July 2015, the FASB issued ASU 2015-14, </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">Revenue from Contracts with Customers</font><font style="font-family:inherit;font-size:10pt;"> </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">(Topic </font><font style="font-family:inherit;font-size:10pt;">606): </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">Deferral of Effective Date</font><font style="font-family:inherit;font-size:10pt;">. This guidance approves a one-year deferral of the effective date of ASU 2014-09. The ASU now permits the Company to adopt this standard effective January 1, 2018. Early application is permitted as of January 1, 2017. In March, April, and May 2016, the FASB issued ASU 2016-08, ASU 2016-10, ASU 2016-11, and ASU 2016-12, </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">Revenue from Contracts with Customers</font><font style="font-family:inherit;font-size:10pt;"> </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">(Topic 606)</font><font style="font-family:inherit;font-size:10pt;">, each of which amends the guidance in ASU 2014-09. When they become effective, these ASUs will replace most existing revenue recognition guidance in GAAP. The Company has assembled an internal revenue task force that meets regularly to discuss and evaluate the overall impact this guidance will have on various revenue streams in the consolidated financial statements and related disclosures. Based on the Company's current assessment, which is still ongoing, the Company does not expect this guidance to have a material effect on its net income, and is continuing to evaluate the impact it will have on its disclosures and controls. The Company plans to adopt these ASUs as of January 1, 2018 using the cumulative effect method and to apply these ASUs only to those contracts that are not completed contracts as of that date. The Company does not currently expect to record a cumulative effect adjustment on the date of initial adoption.</font></div><div style="line-height:120%;padding-top:13px;text-align:left;text-indent:36px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In January 2016, the FASB issued ASU No. 2016-01, </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">Financial Instruments - Overall (Subtopic 825-10): Recognition and Measurement of Financial Assets and Financial Liabilities. </font><font style="font-family:inherit;font-size:10pt;">The amendments in this ASU revise accounting related to (i) the classification and measurement of investments in equity securities and (ii) the presentation of certain fair value changes for financial liabilities at fair value. The amendments in this ASU are effective for the Company beginning on January 1, 2018 and are to be applied through a cumulative effect adjustment to the statement of financial position. Early adoption is permitted under certain circumstances. The adoption of this ASU is not expected to have a material impact on the Company’s consolidated financial statements when adopted on January 1, 2018. </font></div><div style="line-height:120%;padding-top:13px;text-align:left;text-indent:36px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In February 2016, the FASB issued ASU No. 2016-02, </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">Leases (Topic 842)</font><font style="font-family:inherit;font-size:10pt;">. The amendments in this ASU revise the accounting related to lessee accounting. Under the new guidance, lessees will be required to recognize a lease liability and a right-of-use asset for substantially all leases with lease terms in excess of twelve months. The new lease guidance also simplifies the accounting for sale and leaseback transactions primarily because lessees must recognize lease assets and lease liabilities. The amendments in this ASU are effective for the Company beginning on January 1, 2019 and are to be applied through a modified retrospective transition approach for leases existing at, or entered into after, the beginning of the earliest comparative period presented in the financial statements. Early adoption is permitted. The Company has assembled an internal lease task force that meets regularly to discuss and evaluate the overall impact of this guidance on its consolidated financial statements and related disclosures, as well as the expected timing of adoption. The Company is currently gathering information from its existing leases and believes that the new standard will have a material impact on its consolidated balance sheet but will not have a material impact on its results of operations or liquidity. The Company expects to adopt this ASU on January 1, 2019, and continues to evaluate the effect that the implementation of this ASU will have on its consolidated financial statements, related disclosures and controls. </font></div><div style="line-height:120%;padding-top:13px;text-align:left;text-indent:36px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In March 2016, the FASB issued ASU No. 2016-07, </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">Investments - Equity Method and Joint Ventures (Topic 323): Simplifying the Transition to the Equity Method of Accounting. </font><font style="font-family:inherit;font-size:10pt;">The amendments in this ASU eliminate the requirement that when an investment qualifies for use of the equity method as a result of an increase in the level of ownership interest or degree of influence, an investor must adjust the investment, results of operations, and retained earnings retroactively on a step-by-step basis as if the equity method had been in effect during all previous periods that the investment had been held. The amendments in this ASU were effective for the Company beginning on January 1, 2017 and was applied prospectively. The adoption of this ASU did not have a material impact on the Company’s condensed consolidated financial statements. </font></div><div style="line-height:120%;padding-top:13px;text-align:left;text-indent:36px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In March 2016, the FASB issued ASU No. 2016-09, </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">Compensation - Stock Compensation (Topic 718): Improvements to Employee Share-Based Payment Accounting</font><font style="font-family:inherit;font-size:10pt;">. The changes required by this ASU involve several aspects of the accounting for share-based payment transactions, including income tax consequences, classification of awards as either equity or liabilities, classification on the statement of cash flows, and an election on estimating forfeitures. The amendments in this ASU were effective for the Company beginning January 1, 2017. The method of adoption differs for each of the topics covered by the ASU. The primary effect of this ASU for the Company is the presentation of excess tax benefits or deficiencies as a component of income tax expense within the Company's consolidated statements of operations rather than within additional paid-in capital on its consolidated balance sheet. In addition, these excess tax benefits or deficiencies are presented as an operating activity on the consolidated statement of cash flows rather than as a financing activity. </font></div><div style="line-height:120%;padding-top:13px;text-align:left;text-indent:36px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company elected to apply the presentation requirements for cash flows related to excess tax benefits prospectively. Additionally, the Company has elected to continue to estimate forfeitures expected to occur in determining the amount of compensation cost to be recognized each period. This new standard may cause volatility in the Company’s effective tax rates and diluted earnings per share due to the tax effects related to share-based payments being recorded within the Company’s consolidated statements of operations, including a potential increase in the Company’s provision for income taxes if a significant number of outstanding stock awards are exercised at recent levels of the Company’s stock price. </font></div><div style="line-height:120%;padding-top:13px;text-align:left;text-indent:36px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In August 2016, the FASB issued ASU No. 2016-15, </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">Statement of Cash Flows (Topic 230): Classification of Certain Cash Receipts and Cash Payments</font><font style="font-family:inherit;font-size:10pt;">. The amendments in this ASU clarify how certain cash receipts and cash payments should be classified on the statement of cash flows. The new standard is effective for the Company beginning January 1, 2018 and is to be applied retrospectively to all periods presented. The Company has not yet determined the effect that adoption of this ASU will have on its consolidated financial statements.</font></div><div style="line-height:120%;padding-top:13px;text-align:left;text-indent:36px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In October 2016, the FASB issued ASU No. 2016-16, </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">Income Taxes (Topic 740): Intra-Entity Transfers of Assets Other Than Inventory</font><font style="font-family:inherit;font-size:10pt;">. The amendments in this ASU allow entities to recognize the income tax consequences of an intra-entity transfer of an asset other than inventory when the transfer occurs. The current guidance does not allow recognition until the asset has been sold to an outside party. The amendments in this ASU are effective for the Company beginning on January 1, 2018 and are to be applied on a modified retrospective basis. The Company has not yet determined the effect that adoption of this ASU will have on its consolidated financial statements.</font></div><div style="line-height:120%;padding-top:13px;text-align:left;text-indent:36px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In January 2017, the FASB issued ASU No. 2017-04, </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">Intangibles-Goodwill and Other (Topic 350): Simplifying the Test for Goodwill</font><font style="font-family:inherit;font-size:10pt;"> </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">Impairment</font><font style="font-family:inherit;font-size:10pt;">. The amendments in this ASU simplify the test for goodwill impairment by eliminating the second step in goodwill impairment assessments. The Company early adopted this ASU as of January 1, 2017.</font></div><div style="line-height:120%;padding-top:13px;text-align:left;text-indent:36px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In August 2017, the FASB issued ASU No. 2017-12, </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">Derivatives and Hedging (Topic 815): Targeted Improvements to Accounting for Hedging Activities. </font><font style="font-family:inherit;font-size:10pt;">The amendments in this ASU better align an entity’s risk management activities and financial reporting for hedging relationships through changes to both the designation and measurement guidance for qualifying hedging relationships and the presentation of hedge results. The amendments in the new ASU are effective for the Company on January 1, 2018 and are to be applied prospectively. The Company has not yet determined the effect that adoption of this ASU will have on its consolidated financial statements.</font></div></div>
	us-gaap	Loss Contingency Disclosures LossContingencyDisclosures	<div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Contingencies</font></div><div style="line-height:120%;padding-top:13px;text-align:left;text-indent:36px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The majority of the Company’s revenues are from government programs and may be subject to adjustment as a result of: (i) examination by government agencies or contractors, for which the resolution of any matters raised may take extended periods of time to finalize; (ii) differing interpretations of government regulations by different Medicare contractors or regulatory authorities; (iii) differing opinions regarding a patient’s medical diagnosis or the medical necessity of services provided; and (iv) retroactive applications or interpretations of governmental requirements. In addition, the Company’s revenues from commercial payors may be subject to adjustment as a result of potential claims for refunds, as a result of government actions or as a result of other claims by commercial payors.</font></div><div style="line-height:120%;padding-top:13px;text-align:left;text-indent:36px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company operates in a highly regulated industry and is a party to various lawsuits, claims, governmental investigations and audits (including investigations resulting from its obligation to self-report suspected violations of law) and other legal proceedings. The Company records accruals for certain legal proceedings and regulatory matters to the extent that the Company determines an unfavorable outcome is probable and the amount of the loss can be reasonably estimated. As of September 30, 2017 and December 31, 2016, the Company’s total recorded accruals with respect to legal proceedings and regulatory matters, net of anticipated third party recoveries, were approximately </font><font style="font-family:inherit;font-size:10pt;">$51,000</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">$69,000</font><font style="font-family:inherit;font-size:10pt;">, respectively. While these accruals reflect the Company’s best estimate of the probable loss for those matters as of the dates of those accruals, the recorded amounts may differ materially from the actual amount of the losses for those matters, and any anticipated third party recoveries for any such losses may not ultimately be recoverable. Additionally, in some cases, no estimate of the possible loss or range of loss in excess of amounts accrued, if any, can be made because of the inherently unpredictable nature of legal proceedings and regulatory matters, which may be exacerbated by various factors, including that they may involve indeterminate claims for monetary damages or may involve fines, penalties or non-monetary remedies; present novel legal theories or legal uncertainties; involve disputed facts; represent a shift in regulatory policy; are in the early stages of the proceedings; or result in a change of business practices. Further, there may be various levels of judicial review available to the Company in connection with any such proceeding.</font></div><div style="line-height:120%;padding-top:13px;text-align:left;text-indent:36px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The following is a description of certain lawsuits, claims, governmental investigations and audits and other legal proceedings to which the Company is subject.</font></div><div style="line-height:120%;padding-top:13px;text-indent:36px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Inquiries by the Federal Government and Certain Related Civil Proceedings</font></div><div style="line-height:120%;padding-top:13px;text-align:left;text-indent:36px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;text-decoration:underline;">Swoben Private Civil Suit</font><font style="font-family:inherit;font-size:10pt;">: In April 2013, HealthCare Partners (HCP), now known as the Company’s DMG subsidiary, was one of several defendants served with a civil complaint filed by a former employee of SCAN Health Plan (SCAN), an HMO. On July 13, 2009, pursuant to the </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">qui tam</font><font style="font-family:inherit;font-size:10pt;"> provisions of the federal False Claims Act (FCA) and the California False Claims Act, James M. Swoben, as relator, filed his initial </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">qui tam</font><font style="font-family:inherit;font-size:10pt;"> action in the United States District Court for the Central District of California purportedly on behalf of the United States of America and the State of California against SCAN, and certain other defendants whose identities were under seal. The allegations in the complaint relate to alleged overpayments received from government healthcare programs. In 2009 and 2010, the relator twice amended his complaint and added additional defendants, and in November 2011, he filed his Third Amended Complaint under seal alleging violations of the federal FCA and the California False Claims Act, and added additional defendants, including HCP and certain health insurance companies (the defendant HMOs). The allegations in the complaint against HCP relate to patient diagnosis coding to determine reimbursement in the Medicare Advantage (MA) program, referred to as HCC and RAF scores. The complaint sought monetary damages and civil penalties as well as costs and expenses. The U.S. Department of Justice (DOJ) reviewed these allegations and in January 2013 declined to intervene in the case. HCP and the other defendants filed motions to dismiss the Third Amended Complaint, and the court dismissed with prejudice the claims and judgment was entered in September 2013. Upon the plaintiff’s appeal, a panel of the Ninth Circuit overturned the trial court’s ruling and vacated the dismissal of the case. The Company, with certain defendants, petitioned the Ninth Circuit for a rehearing, but in December 2016, the Ninth Circuit rejected the petition and determined the relator should be given an opportunity to amend the complaint, and remanded the case back to district court. In March 2017, the relator filed his Fourth Amended Complaint alleging that HCP and certain health insurance companies employed one-way retrospective reviews that were designed only to identify additional diagnoses that would be submitted to CMS for risk adjustment purposes, and thereby drive higher risk scores that would increase the capitated payments made by the federal government under the MA program. In March 2017, the DOJ partially intervened as to certain defendant HMOs, but elected not to intervene with respect to HCP. In October 2017, the court dismissed a portion of the Fourth Amended Complaint finding that some claims were time-barred and that the relator had waived an alleged theory of liability. On October 18, 2017, the relator filed a Notice of Dismissal of the action as to HCP, and the government consented to the dismissal, as a result of which the suit is now dismissed, without prejudice. </font></div><div style="line-height:120%;padding-top:13px;text-align:left;text-indent:36px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;text-decoration:underline;">2015 U.S. Office of Inspector General (OIG) Medicare Advantage Civil Investigation</font><font style="font-family:inherit;font-size:10pt;">: In March 2015, JSA HealthCare Corporation (JSA), a subsidiary of DMG, received a subpoena from the Office of Inspector General (OIG) for the U.S. Department of Health and Human Services (HHS). The Company has been advised by an attorney with the Civil Division of the DOJ in Washington, D.C. that the subpoena relates to an ongoing civil investigation concerning MA service providers’ risk adjustment practices and data, including identification and verification of patient diagnoses and factors used in making the diagnoses. The subpoena requests documents and information for the period from January 1, 2008 through December 31, 2013, for certain MA plans for which JSA provided services. It also requests information regarding JSA’s communications about patient diagnoses as they relate to certain MA plans generally, and more specifically as related to two Florida physicians with whom JSA previously contracted. The Company is producing the requested information and is cooperating with the government’s investigation.</font></div><div style="line-height:120%;padding-top:13px;text-align:left;text-indent:36px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In addition to the subpoena described above, in June 2015, the Company received a subpoena from the OIG. This civil subpoena covers the period from January 1, 2008 through the present and seeks production of a wide range of documents relating to the Company’s and its subsidiaries’ (including DMG’s and its subsidiary JSA’s) provision of services to MA plans and related patient diagnosis coding and risk adjustment submissions and payments. The Company believes that the request is part of a broader industry investigation into MA patient diagnosis coding and risk adjustment practices and potential overpayments by the government. The information requested includes information relating to patient diagnosis coding practices for a number of conditions, including potentially improper historical DMG coding for a particular condition. With respect to that condition, the guidance related to that coding issue was discontinued following the Company’s November 1, 2012 acquisition of DMG, and the Company notified CMS in April 2015 of the coding practice and potential overpayments. In that regard, the Company has identified certain additional coding practices which may have been problematic and is in discussions with the DOJ about the scope and nature of a review of claims relating to those practices. The Company is cooperating with the government and is producing the requested information. In addition, the Company is continuing to review other DMG coding practices to determine whether there were any improper coding issues. In connection with the DMG merger, the Company has certain indemnification rights against the sellers and an escrow was established as security for the indemnification. The Company has submitted an indemnification claim against the sellers secured by the escrow for any and all liabilities incurred relating to these matters and intends to pursue recovery from the escrow. However, the Company can make no assurances that the indemnification and escrow will cover the full amount of the Company’s potential losses related to these matters. </font></div><div style="line-height:120%;padding-top:13px;text-indent:36px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;text-decoration:underline;">2016 U.S. Attorney Prescription Drug Investigation</font><font style="font-family:inherit;font-size:10pt;">: In early February 2016, the Company announced that its pharmacy services’ wholly-owned subsidiary, DaVita Rx, received a CID from the U.S. Attorney’s Office for the Northern District of Texas. The government is conducting an FCA investigation concerning allegations that DaVita Rx presented or caused to be presented false claims for payment to the government for prescription medications, as well as into the Company’s relationship with pharmaceutical manufacturers. The CID covers the period from January 1, 2006 through the present. In the spring of 2015, the Company initiated an internal compliance review of DaVita Rx during which it identified potential billing and operational issues, including potential write-offs and discounts of patient co-payment obligations, and credits to payors for returns of prescription drugs related to DaVita Rx. The Company notified the government in September 2015 that it was conducting this review of DaVita Rx and began providing regular updates of its review. Upon completion of its review, the Company filed a self-disclosure with the OIG in February 2016 and has been working to address and update the practices it identified in the self-disclosure, some of which overlap with information requested by the U.S. Attorney’s Office. The OIG informed the Company in February 2016 that its submission was not accepted. They indicated that the OIG is not expressing an opinion regarding the conduct disclosed or the Company’s legal positions. The Company is cooperating with the government.</font></div><div style="line-height:120%;padding-top:13px;text-indent:36px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;text-decoration:underline;">Solari Post-Acquisition Matter</font><font style="font-family:inherit;font-size:10pt;">: In 2016, HCP Nevada disclosed to the OIG for the HHS that proper procedures for clinical and eligibility determinations may not have been followed by Las Vegas Solari Hospice (Solari), which was acquired in March 2013 and sold in September 2016 by HCP Nevada. In June 2016, the Company was notified by the OIG that the disclosure submission had been accepted into the OIG’s Self Disclosure Protocol. HCP Nevada had previously made a disclosure and repayment of overpayments to National Government Services (NGS), the Medicare Administrative Contractor for HCP Nevada, for claims submitted by Solari to the federal government prior to DMG’s acquisition of Solari and claims made to the government post-acquisition for which the sellers had certain responsibilities pursuant to a management services agreement. The Company is cooperating with the government in this matter. In October 2017, the Company finalized and executed a settlement agreement with the OIG including payment of an immaterial amount.</font></div><div style="line-height:120%;padding-top:13px;text-align:left;text-indent:36px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;text-decoration:underline;">2017 U.S. Attorney American Kidney Fund Investigation</font><font style="font-family:inherit;font-size:10pt;">: On January 4, 2017, the Company was served with an administrative subpoena for records by the United States Attorney’s Office, District of Massachusetts, relating to an investigation into possible federal health care offenses. The subpoena covers the period from January 1, 2007 through the present, and seeks documents relevant to charitable patient assistance organizations, particularly the American Kidney Fund, including documents related to efforts to provide patients with information concerning the availability of charitable assistance. The Company is cooperating with the government and is producing the requested information.</font></div><div style="line-height:120%;padding-top:13px;text-align:left;text-indent:36px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Although the Company cannot predict whether or when proceedings might be initiated or when these matters may be resolved (other than as described above), it is not unusual for inquiries such as these to continue for a considerable period of time through the various phases of document and witness requests and on-going discussions with regulators. In addition to the inquiries and proceedings specifically identified above, the Company is frequently subject to other inquiries by state or federal government agencies and/or private civil </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">qui tam</font><font style="font-family:inherit;font-size:10pt;"> complaints filed by relators. Negative findings or terms and conditions that the Company might agree to accept as part of a negotiated resolution of pending or future government inquiries or relator proceedings could result in, among other things, substantial financial penalties or awards against the Company, substantial payments made by the Company, harm to the Company’s reputation, required changes to the Company’s business practices, exclusion from future participation in the Medicare, Medicaid and other federal health care programs and, if criminal proceedings were initiated against the Company, possible criminal penalties, any of which could have a material adverse effect on the Company.</font></div><div style="line-height:120%;padding-top:13px;text-indent:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Shareholder Claims</font></div><div style="line-height:120%;padding-top:13px;text-align:left;text-indent:36px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;text-decoration:underline;">Peace Officers’ Annuity and Benefit Fund of Georgia Securities Class Action Civil Suit</font><font style="font-family:inherit;font-size:10pt;">: On February 1, 2017, the Peace Officers’ Annuity and Benefit Fund of Georgia filed a putative federal securities class action complaint in the U.S. District Court for the District of Colorado against the Company and certain executives. The complaint covers the time period of August 2015 to October 2016 and alleges, generally, that the Company and its executives violated</font><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;"> </font><font style="font-family:inherit;font-size:10pt;">federal securities laws concerning the Company’s financial results and revenue derived from patients who received charitable premium assistance from an industry-funded non-profit organization. The complaint further alleges that the process by which patients obtained commercial insurance and received charitable premium assistance was improper and "created a false impression of DaVita’s business and operational status and future growth prospects." The Company disputes these allegations and intends to defend this action accordingly.</font></div><div style="line-height:120%;padding-top:13px;text-align:left;text-indent:36px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;text-decoration:underline;">Blackburn Shareholder Derivative Civil Suit</font><font style="font-family:inherit;font-size:10pt;">: On February 10, 2017, Charles Blackburn filed a derivative shareholder lawsuit in the U.S. District Court for the District of Delaware against the Company, as nominal defendant, the Board of Directors and certain executives. The complaint covers the time period from 2015 to present and alleges, generally, breach of fiduciary duty, unjust enrichment and misrepresentations and/or failures to disclose certain information in violation of the federal securities laws in connection with an alleged practice to direct patients with government-subsidized health insurance into private health insurance plans to maximize the Company’s profits. On August 15, 2017, the District Court consolidated this action with the </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">Gabilondo</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">City of Warren Police and Fire Retirement System</font><font style="font-family:inherit;font-size:10pt;"> suits. The Company disputes these allegations and intends to defend this action accordingly.</font></div><div style="line-height:120%;padding-top:13px;text-align:left;text-indent:36px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;text-decoration:underline;">Gabilondo Shareholder Derivative Civil Suit</font><font style="font-family:inherit;font-size:10pt;">: On May 30, 2017, Antonio Gabilondo filed a derivative shareholder lawsuit in the U.S. District Court for the District of Delaware against the Company, as nominal defendant, the Board of Directors and certain executives. The complaint covers the time period from 2015 to present and alleges, generally, breach of fiduciary duty, unjust enrichment, abuse of control, gross mismanagement, corporate waste, and misrepresentations and/or failures to disclose certain information in violation of the federal securities laws in connection with an alleged practice to direct patients with government-subsidized health insurance into private health insurance plans to maximize the Company’s profits. On August 15, 2017, the District Court consolidated this action with the </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">Blackburn</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">City of Warren Police and Fire Retirement System</font><font style="font-family:inherit;font-size:10pt;"> suits.  The Company disputes these allegations and intends to defend this action accordingly.</font></div><div style="line-height:120%;padding-top:13px;text-indent:36px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;text-decoration:underline;">City of Warren Police and Fire Retirement System Shareholder Derivative Civil Suit</font><font style="font-family:inherit;font-size:10pt;">: On June 9, 2017, the City of Warren Police and Fire Retirement System filed a derivative shareholder lawsuit in the U.S. District Court for the District of Delaware against the Company, as nominal defendant, the Board of Directors, and certain executives. The complaint covers the time period of 2015 to the present and alleges, generally, a breach of fiduciary duty, corporate waste, unjust enrichment, and misrepresentations and/or failures to disclose certain information in violation of the federal securities laws in connection with an alleged practice to direct patients with government-subsidized health insurance into private health insurance plans to maximize the Company’s profits. On August 15, 2017, the District Court consolidated this action with the </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">Blackburn</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">Gabilondo</font><font style="font-family:inherit;font-size:10pt;"> suits. The Company disputes these allegations and intends to defend this action accordingly.</font></div><div style="line-height:120%;padding-top:13px;text-align:left;padding-left:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Other Proceedings</font></div><div style="line-height:120%;padding-top:13px;text-align:left;text-indent:36px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In addition to the foregoing, from time to time the Company is subject to other lawsuits, demands, claims, governmental investigations and audits and legal proceedings that arise due to the nature of its business, including contractual disputes, such as with payors, suppliers and others, employee-related matters and professional and general liability claims. From time to time, the Company also initiates litigation or other legal proceedings as a plaintiff arising out of contracts or other matters.</font></div><div style="line-height:120%;padding-top:13px;text-align:left;text-indent:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Resolved Matters</font></div><div style="line-height:120%;padding-top:13px;text-align:left;text-indent:36px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;text-decoration:underline;">2015 U.S. Attorney Transportation Investigation</font><font style="font-family:inherit;font-size:10pt;">: In February 2015, the Company announced that it received six administrative subpoenas from the OIG for medical records from six different dialysis centers in southern California operated by the Company. Specifically, each subpoena sought the medical records of a single patient of each respective dialysis center. In February 2016, the Company received four additional subpoenas for four additional dialysis centers in southern California. The subpoenas were similarly limited in scope to the subpoenas received in 2015. On February 8, 2017, the Company was served with a </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">qui tam</font><font style="font-family:inherit;font-size:10pt;"> complaint in the U.S. District Court for the Central District of California. The Company was advised by an attorney with the United States Attorney’s Office for the Central District of California that the </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">qui tam</font><font style="font-family:inherit;font-size:10pt;"> was related to the investigation concerning the medical necessity of patient transportation, which was the basis for the subpoenas. The relator alleged that an ambulance company submitted false claims for patient transportation. Although the Company does not provide transportation nor does it bill for the transport of its dialysis patients, the relator alleged that two of its purported clinical staff caused the submission of a small number of those claims through improper certifications of medical necessity. The DOJ has declined to intervene. In April 2017, the court granted the Company's motion to dismiss and dismissed the complaint without prejudice for failing to state a claim upon which relief can be granted. In May 2017, the relator filed a First Amended Complaint and the Company filed an additional motion to dismiss. In June 2017, the court granted the Company’s motion and dismissed the complaint without prejudice. Plaintiff was given until July 24, 2017 to file an amended complaint. Instead, the plaintiff decided not to proceed against the Company and filed a notice of dismissal on July 25, 2017. </font></div><div style="line-height:120%;padding-top:13px;text-indent:36px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;text-decoration:underline;">2011 Suit against the U.S. Department of Veterans Affairs</font><font style="font-family:inherit;font-size:10pt;">: As previously disclosed, the Company had a pending lawsuit in the U.S. Court of Federal Claims against the federal government which was originally filed in May 2011. The lawsuit related to the U.S. Department of Veterans Affairs (VA) underpayment of dialysis services the Company provided from 2005 through 2011 to veterans pursuant to VA regulations. In the first quarter of 2017, the Company received a payment of </font><font style="font-family:inherit;font-size:10pt;">$538,000</font><font style="font-family:inherit;font-size:10pt;"> related to the settlement with the VA. The Company's consolidated entities recognized a net gain of </font><font style="font-family:inherit;font-size:10pt;">$527,000</font><font style="font-family:inherit;font-size:10pt;"> on this settlement. The Company's nonconsolidated and managed entities recognized a gain of </font><font style="font-family:inherit;font-size:10pt;">$9,000</font><font style="font-family:inherit;font-size:10pt;">, of which the Company's equity investment share was </font><font style="font-family:inherit;font-size:10pt;">$3,000</font><font style="font-family:inherit;font-size:10pt;">. The net effect was a net increase of </font><font style="font-family:inherit;font-size:10pt;">$530,000</font><font style="font-family:inherit;font-size:10pt;"> to the Company's operating income.</font></div><div style="line-height:120%;padding-top:13px;text-indent:36px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;text-decoration:underline;">2015 U.S. Department of Justice Vascular Access Investigation and Related</font><font style="font-family:inherit;font-size:10pt;text-decoration:underline;"> </font><font style="font-family:inherit;font-size:10pt;font-style:italic;text-decoration:underline;">Qui Tam</font><font style="font-family:inherit;font-size:10pt;text-decoration:underline;"> </font><font style="font-family:inherit;font-size:10pt;text-decoration:underline;">Litigation</font><font style="font-family:inherit;font-size:10pt;">: In November 2015, the Company announced that RMS Lifeline, Inc., a wholly-owned subsidiary of the Company that operates under the name Lifeline Vascular Access (Lifeline), received a Civil Investigative Demand (CID) from the DOJ. The CID relates to two vascular access centers in Florida that are part of Lifeline’s vascular access business. The CID covers the period from January 1, 2008 through the present. The Company acquired these </font><font style="font-family:inherit;font-size:10pt;">two</font><font style="font-family:inherit;font-size:10pt;"> centers in December 2012. Based on the language of the CID, the DOJ appeared to be looking at whether angiograms performed at the two centers were medically unnecessary and therefore whether related claims filed with federal healthcare programs possibly violated the FCA. Lifeline does not perform dialysis services but instead provides vascular access management services for dialysis patients. The Company cooperated with the government and produced the requested information. The DOJ investigation was initiated pursuant to a complaint brought under the </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">qui tam</font><font style="font-family:inherit;font-size:10pt;"> provisions of the FCA (the Complaint). The Complaint was originally filed under seal in August 2014 in the U.S. District Court, Middle District of Florida, United States ex. rel James Spafford v. DaVita HealthCare Partners, Inc., et al., Case Number 6:14-cv-1251-Orl-41DAB, naming several doctors along with the Company as defendants. In December 2015, a First Amended Complaint was filed under seal. In May 2016, the First Amended Complaint was unsealed. The First Amended Complaint alleged violations of the FCA due to the submission of claims to the government for allegedly medically unnecessary angiograms and angiography procedures at the two vascular access centers as well as employment-related claims. The Complaint covers alleged conduct dating from July 2008, prior to the Company’s acquisition of the centers, to the present. The DOJ declined to intervene. In January 2017, the Company finalized and executed a settlement agreement with the relator and the government for an immaterial amount, and in April 2017, the court dismissed the case with prejudice.</font></div><div style="line-height:120%;padding-top:13px;text-align:left;text-indent:36px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;text-decoration:underline;">Vainer Private Civil Suit</font><font style="font-family:inherit;font-size:10pt;">: As previously disclosed, the Company received a subpoena for documents from the OIG relating to the pharmaceutical products Zemplar, Hectorol, Venofer, Ferrlecit and erythropoietin (EPO), as well as other related matters, covering the period from January 2003 to December 2008. The Company subsequently learned that the allegations underlying this inquiry were made as part of a civil complaint filed by relators, Daniel Barbir and Dr. Alon Vainer, pursuant to the </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">qui tam</font><font style="font-family:inherit;font-size:10pt;"> provisions of the federal FCA. The relators also alleged that the Company’s drug administration practices for the Company’s dialysis operations for Vitamin D and iron agents from 2003 through 2010 fraudulently created unnecessary waste, which was billed to and paid for by the government. In June 2015, the Company finalized the terms of the settlement with plaintiffs, including a settlement amount of </font><font style="font-family:inherit;font-size:10pt;">$450,000</font><font style="font-family:inherit;font-size:10pt;"> and attorney fees and other costs of </font><font style="font-family:inherit;font-size:10pt;">$45,000</font><font style="font-family:inherit;font-size:10pt;"> which was paid in 2015.</font></div><div style="line-height:120%;padding-top:13px;text-align:left;text-indent:36px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;text-decoration:underline;">2011 U.S. Attorney Medicaid Investigation</font><font style="font-family:inherit;font-size:10pt;">: In October 2011, the Company announced that it would be receiving a request for documents, which could include an administrative subpoena from the OIG. Subsequent to the Company’s announcement of this 2011 U.S. Attorney Medicaid Investigation, the Company received a request for documents in connection with the inquiry by the U.S. Attorney’s Office for the Eastern District of New York. The request related to payments for infusion drugs covered by Medicaid composite payments for dialysis. The Company cooperated with the government and produced the requested documents. In April 2014, the Company reached an agreement in principle with the government. In March 2016, the Company finalized and executed settlement agreements with the State of New York and the DOJ, including a settlement payment of an immaterial amount.</font></div><div style="line-height:120%;padding-top:13px;text-align:center;text-indent:36px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">* * *</font></div><div style="line-height:120%;padding-top:13px;text-indent:36px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Other than as described above, the Company cannot predict the ultimate outcomes of the various legal proceedings and regulatory matters to which the Company is or may be subject from time to time, including those described in this Note 10, or the timing of their resolution or the ultimate losses or impact of developments in those matters, which could have a material adverse effect on the Company’s revenues, earnings and cash flows. Further, any legal proceedings or regulatory matters involving the Company, whether meritorious or not, are time consuming, and often require management’s attention and result in significant legal expense, and may result in the diversion of significant operational resources, or otherwise harm the Company’s business, financial results or reputation.</font></div></div>

Files In Submission

Name	View Source	Status
0000927066-17-000088-index-headers.html	Edgar Link	pending
0000927066-17-000088-index.html	Edgar Link	pending
0000927066-17-000088.txt	Edgar Link	pending
0000927066-17-000088-xbrl.zip	Edgar Link	pending
dva-20170930.xml	Edgar Link	completed
dva-20170930.xsd	Edgar Link	pending
dva-20170930_cal.xml	Edgar Link	unprocessable
dva-20170930_def.xml	Edgar Link	unprocessable
dva-20170930_lab.xml	Edgar Link	unprocessable
dva-20170930_pre.xml	Edgar Link	unprocessable
dva-93017ex101.htm	Edgar Link	pending
dva-93017ex102.htm	Edgar Link	pending
dva-93017ex103.htm	Edgar Link	pending
dva-93017ex121.htm	Edgar Link	pending
dva-93017ex311.htm	Edgar Link	pending
dva-93017ex312.htm	Edgar Link	pending
dva-93017ex321.htm	Edgar Link	pending
dva-93017ex322.htm	Edgar Link	pending
dva-93017x10q.htm	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
Financial_Report.xlsx	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R53.htm	Edgar Link	pending
R54.htm	Edgar Link	pending
R55.htm	Edgar Link	pending
R56.htm	Edgar Link	pending
R57.htm	Edgar Link	pending
R58.htm	Edgar Link	pending
R59.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R60.htm	Edgar Link	pending
R61.htm	Edgar Link	pending
R62.htm	Edgar Link	pending
R63.htm	Edgar Link	pending
R64.htm	Edgar Link	pending
R65.htm	Edgar Link	pending
R66.htm	Edgar Link	pending
R67.htm	Edgar Link	pending
R68.htm	Edgar Link	pending
R69.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R70.htm	Edgar Link	pending
R71.htm	Edgar Link	pending
R72.htm	Edgar Link	pending
R73.htm	Edgar Link	pending
R74.htm	Edgar Link	pending
R75.htm	Edgar Link	pending
R76.htm	Edgar Link	pending
R77.htm	Edgar Link	pending
R78.htm	Edgar Link	pending
R79.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R80.htm	Edgar Link	pending
R81.htm	Edgar Link	pending
R82.htm	Edgar Link	pending
R83.htm	Edgar Link	pending
R84.htm	Edgar Link	pending
R85.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$DVA
DAVITA INC. Stock $dva

2017 Q4 Form 10-Q Financial Statement

#000092706617000088 Filed on November 07, 2017

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$DVA DAVITA INC. Stock $dva

2017 Q4 Form 10-Q Financial Statement

#000092706617000088 Filed on November 07, 2017

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$DVA
DAVITA INC. Stock $dva